Author

J A Zwiebel

Observed names: J. A. Zwiebel, J. Zwiebel, J.A. Zwiebel, JA Zwiebel, Jamie Zwiebel

Institutions: National Institutes of Health, National Cancer Institute

Observed institutions: National Institutes of Health, Johns Hopkins University, The University of Texas at San Antonio Health Science Center, Georgetown University, Wayne State University, University of Michigan, National Cancer Institute

OpenAlex ID: A5032659617

Detection and partial characterization of collagen synthesis stimulating activities in rat mammary adenocarcinomas.

1983 · M Bano, J A Zwiebel, et al. · Journal of Biological Chemistry · 48

Long-term in vivo expression of genes introduced by retrovirus-mediated transfer into mammary epithelial cells

1991 · G H Smith, D Gallahan, et al. · Journal of Virology · 44

Role of bcl-2 and IL-5 in the regulation of anti-IgM-induced growth arrest and apoptosis in immature B cell lines. A cooperative regulation model for B cell clonal deletion.

1994 · H Kamesaki, J A Zwiebel, et al. · The Journal of Immunology · 28

New agents for acute myelogenous leukemia

2000 · JA Zwiebel · Leukemia · 19

Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor MS-275 in combination with 13-cis retinoic acid in patients with advanced solid tumors

2006 · R. Pili, M. Rudek, et al. · Journal of Clinical Oncology · 8

Expanded phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors

2008 · C. Townsley, A. M. Oza, et al. · Journal of Clinical Oncology · 5

Phase II study of fenretinide in patients with small cell lung cancer (SCLC) with progression after first- or second-line chemotherapy

2004 · B. J. Schneider, F. Worden, et al. · Journal of Clinical Oncology · 5

National Cancer Institute Formulary: A Public‐Private Partnership Providing Investigators Access to Investigational Anticancer Agents

2016 · JV Cristofaro, SS Ansher, et al. · Clinical Pharmacology & Therapeutics · 1

1997 · V. Sung, D.A. Cattell, et al. · Clinical & Experimental Metastasis · 1

A Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of GTI2040 (GTI), a novel ribonucleotide reductase inhibitor in combination with gemcitabine (Gem) in adult patients (pts) with advanced solid tumors.

2007 · Chris H. Takimoto, Quincy Chu, et al. · Molecular Cancer Therapeutics

Bystander tumoricidal effect of murine and human vascular endothelial cells transduced with the herpes thymidine kinase gene

1996 · Ning Su, John Ojeifo, et al. · Proceedings of the American Association for Cancer Research Annual Meeting

Works count: 11

Citation count: 159

H-index: 5

I10-index: 4